Evidence map›Paper›PMID 41652007›Full record

ArticleBJC reports2026

STAR (stroma-tumor AI risk) assessment: association of AI-derived tumor-stroma proportion with patient survival provides added prognostic value beyond KELIM in epithelial ovarian cancer.

Arpit Aggarwal, Morgann Madill, Mayukhmala Jana, Tilak Pathak, Timothy K Starr, Boris Winterhoff, Katelyn M Tessier, Britt K Erickson, Andrew C Nelson, Emil Lou and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arpit Aggarwal *Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA, USA.
Morgann Madill *Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Mayukhmala JanaDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA, USA.
Tilak PathakDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA, USA.
Timothy K StarrMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Boris WinterhoffMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Katelyn M TessierMasonic Cancer Center, Biostatistics Core, Minneapolis, MN, USA.
Britt K EricksonMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Andrew C NelsonDepartment of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, MN, USA.
Emil LouDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Anant MadabhushiDepartment of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA, USA. anantm@emory.edu.ORCID http://orcid.org/0000-0002-5741-0399
Martina BazzaroMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA. mbazzaro@umn.edu.ORCID http://orcid.org/0000-0002-9426-9515

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Pathology CoreU54CA254566 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MADABHUSHI, ANANT · 2020 to 2024
$5.0M
University of Minnesota Clinical Center for the Study of Pancreatic DiseaseU01DK126300 · NIDDK · UNIVERSITY OF MINNESOTA · PI GREGORY J BEILMAN, Melena D. Bellin · 2020 to 2026
$3.9M
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
Novel Radiomics for Predicting Response to Immunotherapy for Lung CancerR01CA257612 · NCI · EMORY UNIVERSITY · PI Anant Madabhushi, Vamsidhar Velcheti · 2021 to 2026
$2.7M
RadxTools for assessing tumor treatment response on imagingU01CA248226 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI TIWARI, PALLAVI, VISWANATH, SATISH EASWAR · 2020 to 2022
$1.4M
HistoTools: A suite of digital pathology tools for quality control, annotation and dataset identificationU01CA239055 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JANOWCZYK, ANDREW ROBERT, MADABHUSHI, ANANT · 2019 to 2022
$1.0M
Biostatistics Core - NIH P30 CA77598BLRD VA I01 BX004121BLRD VA IK6 BX006185National Center for Advancing Translational Sciences of the National Institutes of Health Award Number 7NCI NIH HHS P30 CA077598NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA249992NCI NIH HHS R01CA249992-01A1, R01CA202752-01A1, R01CA208236-01A1, R01CA216579-01A1, R01CA220581-01A1, R01CA257612-01A1, 1U01CA239055-01, 1U01CA248226-01, 1U54CA254566-01NCI NIH HHS R01 CA257612NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U54 CA254566NCRR NIH HHS 1 C06 RR12463-01NCRR NIH HHS C06 RR012463NHLBI NIH HHS 1R01HL15127701A1, R01HL15807101A1NIBIB NIH HHS 1R43EB028736-01NIBIB NIH HHS R43 EB028736NIDDK NIH HHS U01 DK126300Office of the Assistant Secretary of Defense for Health Affairs W81XWH-19-1-0668, W81XWH-15-1-0558, W81XWH-20-1-0851, W81XWH-18-1-0440, W81XWH-20-1-0595Research Scholar Grant RSG-22-022-01-CDPUniversity of Minnesota Clinical Center for the Study of Pancreatic Disease, part of The Chronic Pancreatitis Diabetes Pancreatic Cancer research (CPDPC) consortium 5U01DK126300-03VA Merit Review Award IBX004121A
6 · The paper itself

Abstract

backgroundThere remains a critical need for prognostic biomarkers of treatment response in epithelial ovarian cancer (EOC). The KELIM score, derived from the rate of CA-125 elimination during the first 100 days of treatment, is a clinically available biomarker of treatment response to platinum-based chemotherapy, its utility is limited by the need for post-treatment data. Tumor-stroma proportion (TSP) has emerged as a prognostic biomarker across several malignancies. Studies from our group have shown that high TSP (≥50% stroma content assessed by pathologist evaluation, TSP

methodsWe compared the prognostic value of TSP and KELIM by analyzing manual pathologist (TSP

resultsIn this cohort, we showed the prognostic significance of TSP

conclusionThese findings support AI-derived TSP as a pre-treatment prognostic biomarker for EOC that complements KELIM.

Identifiers

PMID41652007
PMCPMC12881467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.